Management of cardiometabolic complications in polycystic ovary syndrome: Unmet needs

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder and the most common cause of androgen excess in reproductive-age women. The heterogeneity of the clinical presentation in PCOS patients suggests the involvement of multiples abnormal physiological pathways. In addition, women with PCOS have a high prevalence of cardiometabolic risk factors. Unfortunately, limited effective evidence-based therapeutic agents are available to treat the cardiometabolic complications in PCOS patients. Insights from recent studies highlight the multiple opportunities to deliver timely effective medical care for women with PCOS. This perspective manuscript aims to highlight the unmet need for effective and safe management of the cardiometabolic complications in PCOS patients.

Automated summary

PCOS is the most common endocrine disorder in reproductive-age women, with heterogeneous clinical presentations and involvement of multiple abnormal physiological pathways. Women with PCOS also have a high prevalence of cardiometabolic risk factors, but there is limited evidence-based therapeutic agents available to treat these complications. Recent studies suggest opportunities for timely effective medical care for women with PCOS, highlighting the unmet need for effective and safe management of the cardiometabolic complications in these patients.